RECORDATI
Recordati S.p.A., a prominent player in the pharmaceutical industry, is headquartered in Luxembourg (LU) and operates extensively across Europe, North America, and other global markets. Founded in 1926, Recordati has established itself as a leader in the development and marketing of innovative medicines, particularly in the fields of rare diseases and specialty pharmaceuticals. The company’s core offerings include a diverse range of prescription drugs, with a strong emphasis on treatments for rare diseases, urology, and cardiovascular conditions. Recordati's commitment to research and development sets it apart, enabling the introduction of unique therapies that address unmet medical needs. With a robust market position, Recordati has achieved significant milestones, including strategic acquisitions and partnerships that enhance its portfolio and global reach.
DitchCarbon Score
How does RECORDATI's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
RECORDATI's score of 55 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
RECORDATI's reported carbon emissions
In 2024, RECORDATI reported total carbon emissions of approximately 346,511,000 kg CO2e, with Scope 1 emissions at about 37,280,000 kg CO2e, Scope 2 emissions (location-based) at approximately 8,785,000 kg CO2e, and significant Scope 3 emissions of around 307,517,000 kg CO2e. The company has set ambitious targets to reduce its emissions, aiming for a 42% reduction in both Scope 1 and Scope 2 emissions by 2030, using 2023 as the baseline year. This commitment aligns with the Science Based Targets initiative (SBTi) and reflects a strong dedication to climate action. In previous years, RECORDATI has made notable progress in reducing its emissions. For instance, in 2023, Scope 1 emissions decreased by about 3.1% compared to 2022, while Scope 2 emissions saw a reduction of approximately 1.9%. The company is also committed to purchasing 100% renewable electricity for its production and packaging sites by 2025, further enhancing its sustainability efforts. RECORDATI's emissions data is cascaded from its parent company, Recordati Industria Chimica e Farmaceutica S.p.A., ensuring a comprehensive approach to tracking and managing carbon emissions across its operations. The company continues to focus on measuring and reducing its Scope 3 emissions, which represent a significant portion of its overall carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 27,785,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 10,302,000 | 00,000,000 | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
RECORDATI is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
